Era
Membership Organizations · Italy · 11-50 Employees
View Company Info for Free
Overview
Headquarters
Strada Dei Mercati 16/a, Parma, Emilia-R...Phone Number
+421 513211633Website
www.era-online.orgRevenue
<$5 MillionIndustry
About Era
Is Era your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check if Era has recently received funding, and reach out quickly before it becomes old news!
Check out if Era is spiking on competitors!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Click to see if Era had a recent Job posting/layoffs
Earning: See what the market has to say on Era recently announced quarterly report
Product Launch: Get notified when Era launches new products
Funding: Get notified immidiatlly once Era has new funding data
Era, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at Era
Recommended Actions
Reach out to Masked Content who joined Era as Masked Content
Find 3 more new buyers
Company Profile Activity
Activity Insights
Era is experiencing very low activity levels compared to other companies in the Organizations sector.
What does this means?
Era is drawing exceptional interest within the Organizations industry, suggesting notable developments or strong market momentum, learn more about Era.
Era Tech Stack
A closer look at the technologies used by Era
Era News & Media
Novartis presents latest Phase III Fabhalta® (iptacopan) data in C3 glomerulopathy (C3G) showing clinically meaningful and statistically significant 35.1% proteinuria reduction vs. placebo
Basel, May 25, 2024 – Novartis today presented results from the 6-month, double-blind period of the Phase III APPEAR-C3G study of Fabhalta® (iptacopan) at the late-breaking clinical trials session of the European Renal Association (ERA) Congress1. Patients treated with Fabhalta in addition to supportive care achieved a 35.1% (p=0.0014) reduction in proteinuria (as measured by 24-hour urine protein to creatinine ratio [UPCR]) at 6 months when compared to placebo on top of supportive care1. In
Top Membership Organizations Companies
Frequently Asked Questions Regarding Era
The European Renal Association (ERA) is a prominent professional society in nephrology, dedicated to enhancing kidney health accessibility across Europe. It offers a range of educational resources, networking opportunities, and scientific publications aimed at nephrologists and healthcare professionals. ERA organizes congresses, seminars, and provi... Read More